Finding Your CAR: The Road Ahead for Engineered T Cells
- PMID: 38697513
- DOI: 10.1016/j.ajpath.2024.04.002
Finding Your CAR: The Road Ahead for Engineered T Cells
Abstract
Adoptive cellular therapy using chimeric antigen receptors (CARs) has transformed immunotherapy by engineering T cells to target specific antigens on tumor cells. As the field continues to advance, pathology laboratories will play increasingly essential roles in the complicated multi-step process of CAR T-cell therapy. These include detection of targetable tumor antigens by flow cytometry or immunohistochemistry at the time of disease diagnosis and the isolation and infusion of CAR T cells. Additional roles include: i) detecting antigen loss or heterogeneity that renders resistance to CAR T cells as well as identifying alternative targetable antigens on tumor cells, ii) monitoring the phenotype, persistence, and tumor infiltration properties of CAR T cells and the tumor microenvironment for factors that predict CAR T-cell therapy success, and iii) evaluating side effects and biomarkers of CAR T-cell cytotoxicity such as cytokine release syndrome. This review highlights existing technologies that are applicable to monitoring CAR T-cell persistence, target antigen identification, and loss. Also discussed are emerging technologies that address new challenges such as how to put a brake on CAR T cells. Although pathology laboratories have already provided companion diagnostic tests important in immunotherapy (eg, programmed death-ligand 1, microsatellite instability, and human epidermal growth factor receptor 2 testing), we draw attention to the exciting new translational research opportunities in adoptive cellular therapy.
Copyright © 2024. Published by Elsevier Inc.
Conflict of interest statement
Disclosure Statement None declared.
Similar articles
-
Chimeric antigen receptor (CAR)-T-cell therapy in non-small-cell lung cancer (NSCLC): current status and future perspectives.Cancer Immunol Immunother. 2021 Mar;70(3):619-631. doi: 10.1007/s00262-020-02735-0. Epub 2020 Oct 6. Cancer Immunol Immunother. 2021. PMID: 33025047 Free PMC article. Review.
-
The Role of Immunological Synapse in Predicting the Efficacy of Chimeric Antigen Receptor (CAR) Immunotherapy.Cell Commun Signal. 2020 Aug 25;18(1):134. doi: 10.1186/s12964-020-00617-7. Cell Commun Signal. 2020. PMID: 32843053 Free PMC article. Review.
-
Challenges and Prospects of Chimeric Antigen Receptor T-cell Therapy for Metastatic Prostate Cancer.Eur Urol. 2020 Mar;77(3):299-308. doi: 10.1016/j.eururo.2019.08.014. Epub 2019 Aug 28. Eur Urol. 2020. PMID: 31471138 Review.
-
The making and function of CAR cells.Immunol Lett. 2019 Aug;212:53-69. doi: 10.1016/j.imlet.2019.06.002. Epub 2019 Jun 7. Immunol Lett. 2019. PMID: 31181279 Free PMC article. Review.
-
CAR T Cells for Solid Tumors: New Strategies for Finding, Infiltrating, and Surviving in the Tumor Microenvironment.Front Immunol. 2019 Feb 5;10:128. doi: 10.3389/fimmu.2019.00128. eCollection 2019. Front Immunol. 2019. PMID: 30804938 Free PMC article. Review.
Publication types
Grants and funding
LinkOut - more resources
Full Text Sources
Research Materials